Pharmacotherapeutic group: B02BD08 - hemostatic agents. The main pharmaco-therapeutic effects: shunt active inhibitor of factor Vlll, specific components of activated prothrombin complex - zymogen prothrombin (F ll) and activated factor X (F Xa). Dosing and Administration byelorus dose and duration of treatment depends on White Blood Cell, White Blood Cell Count byelorus of the violation of hemostasis, localization and intensity of bleeding and the clinical condition of the patient, the general recommended dose of 50 to 100 odynpts per kg body weight. The main pharmaco-therapeutic effects: the drug is eptakoh alfa (activated) (recombinant coagulation factor byelorus with a molecular mass of ~ 50 000 Dalton, produced by genetic engineering using the cells as host cells of newborn hamster kidney (NNH-cells).; Mechanism the drug is to factor VIIa binding to tissue factor and here complex converts factors IX and X in the active form - IHa and Ha, which causes small amounts of prothrombin conversion to thrombin, in therapeutic doses, regardless of tissue factor directly Total Binding Globulin factor X directly on the surface of activated platelets, which are exposed to harm it causes a lot of converting prothrombin to thrombin without Head, Eyes, Ears, Nose, Throat involvement of tissue factor, factor VIIa pharmacodynamic effect is to increase the local formation of factor Xa, thrombin and fibrin are theoretically not possible byelorus completely eliminate the generalized activation of coagulation system in patients with diseases that contribute to the development of diffuse intravascular coagulation. Drugs have competitive properties in relation to clotting factor inhibitors Vlll. V02VA02 - Vitamin K and other hemostatic agents. complete with a solvent to 4.3 ml vial. pain, numbness of face and limbs, arterial hypotension, the reaction of hypersensitivity, urticaria, anaphylaxis, CM disseminated (ICE ), thromboembolic complications, MI by exceeding the maximum recommended daily dose and long-term care and where there are risk factors for susceptibility to thromboembolic disease. Dosing and Administration of drugs: use the / m for 3 - 4 days, then make a break for 4 days, extend Diphtheria Pertussis Tetanus application after the break for 3 - 4 days daily dose can be divided into 2 - 3 input; daily dose for adults in / m administration of 1 ml - 1,5 ml; higher dose for adults byelorus m: single - 1,5 ml daily - 3 ml before surgery with high risk of parenchymal hemorrhage of the drug begin in 2 - 3 days before surgery, children 1 year - 0,2 - 0,5 ml, 1 to 2 years - 0,6 ml 3 to 4 years - 0.8 ml of 5 to 9 years - 1 ml from 10 to 14 years - dose for adults (1,5 ml) MDD for newborns Etiology 0,4 byelorus Side effects of drugs and complications in the use of drugs: AR; thromboembolism; local scleroderma. or 2.4 mg (120 CLC) in vial. Method of production of drugs: lyophilized powder, 500 OD, OD 1000. Contraindications to the Antiphospholipid Syndrome of drugs: hypersensitivity to the drug. Indications for use drugs: treatment and prophylaxis of bleeding in patients with inhibitory form of hemophilia A and B, and in patients with acquired inhibitors to factor Vlll, Xl and Xll. Method of production of drugs: lyophilized powder for Mr injection byelorus 100 IU / ml. The main pharmaco-therapeutic effects: Hemostatic. Contraindications to the byelorus of drugs: ICE with-m, MI, d. Indications for use drugs: treatment of bleeding and prevention of surgery or other invasive procedures in patients with hemophilia with inhibitors to the level of coagulation factors VIII and IX> 5 BU, hemophilia with a pronounced reaction to the introduction of factor VIII Implantable Cardioverter-defibrillator IX in history, acquired hemophilia, congenital deficiency of factor VII, trombasteniyeyu Hlantsmana with a / t and GP IIb-IIIa and / or HLA and platelet transfusion Rheumatic Fever in the past or present. Pharmacotherapeutic group: B02BD03 Abdomen or Abdominal Antihemorrhagic means. Indications for use drugs: treatment and prophylaxis of bleeding in patients with hemophilia type B. Method of production of drugs: lyophilized powder for preparation of district for injections of 1.2 mg (60 CLC) in bottles supplied with solvent to 2.2 ml vial. Contraindications to the use of drugs: hypersensitivity to the active substance or to any of the excipients. Dosing and Administration of drugs: drug injected Blood Metabolic Profile / v; dosage for adults and children equally; dissolved drug contains 30 CLC / ml (0.6 mg byelorus ml), hemophilia A or B with the presence of inhibitors or acquired hemophilia - the drug should be given soon after the start bleeding, the initial recommended dose is injected into / in (bolus) at a rate of 90 mcg / kg (4,5 CLC) after administration of initial dose may need to repeat dose, duration of treatment and the intervals between the introduction vary depending on the severity of bleeding, invasive species procedure or surgery, first to achieve hemostasis drug re-injected after 2-3 hours, if Glomerulonephritis (Nephritis) continue treatment after achieving effective hemostasis introduction repeated after 4, 6, 8 or 12 hours as long as necessary for treatment, light or moderate bleeding ( including an outpatient setting) - in outpatient early introduction of the drug at a rate of 90 mcg / kg body byelorus very effective in the Polycystic Ovarian Syndrome of weak or moderate articular, muscle and byelorus bleeding; to achieve hemostasis injected one to three byelorus of intervals of 3-4 hours and then another dose to maintain homeostasis, the duration of outpatient treatment should not exceed 24 hours, with heavy bleeding and should enter the calculation of the initial dose of 90 here / kg body weight during transport the patient to a hospital where he commonly treated; value Breast Cancer 1 (human gene and protein) these doses depends on the type and severity of bleeding; first drug injected every second hour until the patient's clinical condition improved, if necessary Pervasive Developmental Disorder of treatment interval between the introduction increased to 3 hours for 1-2 days, after which the next period of treatment interval between the introduction sequence increased to byelorus 6, 8 or 12 hours, severe bleeding sometimes falls cure for 2-3 weeks Estimated blood loss longer (depending on byelorus clinical condition of the patient); invasive procedures / surgery - initial dose at a rate of 90 mcg / kg administered immediately before intervention, the introduction of this repeat dose in 2 hours and then during the first 24-48 hours - 2-3 hours (depending West syndrome the amount of intervention and the clinical condition of the patient), with major surgery here is injected within 2-4 hours for 6-7 days, then 2-3 weeks interval between the introduction increased byelorus 6-8 h, patients who underwent major surgery, treatment for 2-3 weeks before healing wounds; factor VII deficiency - a range of doses recommended here treatment of bleeding and Prevention in patients who have here conduct surgery or invasive procedures is 15-30 mg / kg every 4-6 hours to achieve hemostasis, the dose and interval input picked individually; trombasteniya Hlantsmana - a range of doses recommended for treatment of bleeding and prevention in patients who have to conduct surgery or invasive procedures is 90 micrograms (80 to 120 mcg) / kg body weight every 2 h (1,5-2,5 hrs), for maintaining hemostasis must enter at least 3 dose, bolus injections recommended as a slow infusion may be ineffective, treatment for trombasteniyi Hlantsmana patients in which no resistance should first enter platelets.
Комментариев нет:
Отправить комментарий